Clinical Trial Update: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating re-challenge immunotherapy with cromolyn, TQB2102, and panpulimab in immune-refractory triple-negative breast cancer; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Cromolyn (cromolyn sodium)
• Panpulimab
• TQB2102

Snippet

Sponsor: Fudan University | Conditions: Triple -Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING